Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.
ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH
© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Tissue-Free vs Tumor-Informed Circulating Tumor DNA Assays in Early Triple Negative Breast Cancer | 0 | 12.99 | 13-08-2026 |
| 2 | Scientists uncover the hidden nerve network fueling breast cancer | 0 | 8.15 | 17-08-2026 |
| 3 | Comprehensive genomic profiling with subsequent molecularly guided therapy improves outcomes over platinum-based chemotherapy in previously untreated, unfavourable CUP | 0 | 16.41 | 22-09-2026 |
| 4 | FDA Approves Trodelvy — A Breakthrough Treatment For One Of The Deadliest Breast Cancers | 8 | 7 | 30-06-2026 |
| 5 | В РФ зарегистрировали препарат против тройного негативного рака молочной железы | 0 | 8.1 | 19-08-2026 |
| 6 | PARP Inhibitors for Breast Cancer Treatment | 0 | 5.63 | 01-05-2024 |
| 7 | Gut bacteria may influence estrogen-related cancers, review finds | 0 | 5 | 06-07-2026 |
| 8 | Gut bacteria may influence estrogen-related cancers, review finds | 0 | 7 | 06-07-2026 |
| 9 | Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer | 0 | 7 | 25-06-2026 |